这些是副作用吗?肠易激综合征临床试验中报告的肠外症状在基线时可能更严重
本研究分析一项为期6周的肠易激综合征临床试验数据,173名参与者随机接受双盲薄荷油、双盲安慰剂或常规治疗。基线时每组每人约报告5个肠外症状,至研究结束时平均降至3个,所有组内变化均具统计学显著性(每组P < .001),且3组平均症状严重程度均显著下降(P < .001)。结论提示肠易激综合征患者在基线时即常存在肠外症状,且这些症状在试验过程中总体改善,与治疗分组无关。
要点
- 肠易激综合征临床试验中报告的肠外症状可能在基线时即已存在且更严重。
- 基线时每组每人约报告5个肠外症状,研究结束时平均降至3个(每组P < .001)。
- 3组平均症状严重程度从基线至最终评估均显著下降(P < .001)。
核心结论
- 肠易激综合征参与者常在基线时即经历肠外症状,且这些症状在临床试验过程中严重程度总体改善,与治疗分组无关。
- 临床试验开始时系统评估肠外症状对于更明确地判断这些症状是否可归因于研究药物的不良事件是必要的。
研究设计与样本
- 分析一项为期6周的肠易激综合征临床试验数据,参与者随机接受双盲薄荷油、双盲安慰剂或常规治疗。
- 肠外症状在基线和研究结束时进行评估。
- 本分析纳入173名参与者(双盲薄荷油组30名、常规治疗组72名、双盲安慰剂组71名)。
主要发现
- 基线时每组每名参与者约报告5个肠外症状。
- 每名参与者的症状数至研究结束访视时平均降至3个,所有组内变化均具统计学显著性(每组P < .001)。
- 评估单个肠外症状时,大多数参与者未报告新发或加重的症状。
- 从基线评估至最终评估,3组平均症状严重程度均显著下降(P < .001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Many of the reported adverse events in clinical trials of irritable bowel syndrome are extraintestinal symptoms, which typically are assessed by open-ended questions during the trial and not at baseline. This may lead to misattribution of some pre-existing symptoms as side effects to the treatment. METHODS: The current study analyzed data from a 6-week clinical trial of irritable bowel syndrome. Participants were randomized to receive double-blind peppermint oil, double-blind placebo, or treatment as usual. Extraintestinal symptoms were assessed at baseline and at the end of the study. RESULTS: This analysis included 173 participants (30 received double-blind peppermint oil, 72 received treatment as usual, and 71 received double-blind placebo). At baseline, each group reported approximately 5 extraintestinal symptoms per participant. The number of symptoms per participant decreased to an average of 3 by the end-of-study visit, and this change was statistically significant in all groups (P < .001 for each group). When evaluating individual extraintestinal symptoms, the majority of participants did not report new/worse symptoms. In fact, between the baseline assessment and the final assessment, the average symptom severity decreased significantly in all 3 groups (P < .001). CONCLUSIONS: Our study suggests that participants with irritable bowel syndrome often experience extraintestinal symptoms at baseline and that these symptoms generally improve in severity over the course of a clinical trial, regardless of the treatment arm. Systematic assessment of extraintestinal symptoms at the beginning of a clinical trial is necessary to determine more definitively whether these symptoms may be considered an adverse event attributable to a study medication.
引用
- Ballou S, Hassan R, Nee J, et al. Are They Side Effects? Extraintestinal Symptoms Reported During Clinical Trials of Irritable Bowel Syndrome May Be More Severe at Baseline. Clin Gastroenterol Hepatol. 2022. PMID: 35339669. doi:10.1016/j.cgh.2022.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。